ENDRA Life Sciences (NDRA) Return on Capital Employed (2017 - 2026)

ENDRA Life Sciences has disclosed Return on Capital Employed across 10 years of filings, most recently posting 77.57% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 21530.0% year-over-year to 77.57%; the TTM figure through Mar 2026 stood at 77.57% (up 21530.0% YoY), while the FY2025 annual figure was 43.38%, up 17305.0% from the prior year.
• Return on Capital Employed slipped to 77.57% in Q1 2026, from 68.39% in the prior quarter.
• Over the last five years, Return on Capital Employed for NDRA reached as high as 68.39% in Q4 2025 and fell as low as 532.16% in Q3 2025.
• The 5-year median for Return on Capital Employed is 167.65% (2023), against an average of 190.53%.
• Annual changes were most pronounced in 2025 — Return on Capital Employed sank 43935 bps — and 2026, when it jumped 21530 bps.
• A 5-year view of Return on Capital Employed shows it stood at 144.51% in 2022, then fell by 16 bps to 167.65% in 2023, then retreated by 11 bps to 186.17% in 2024, then surged by 63 bps to 68.39% in 2025, then dropped by 13 bps to 77.57% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 77.57%, 68.39%, and 532.16% for Q1 2026, Q4 2025, and Q3 2025 respectively.